SERUM AMYLOID P AND DERMAL WOUND FIBROSIS
SERUM AMYLOID P AND DERMAL WOUND FIBROSIS
批准号:
7659827
负责人:
OLUYINKA OLUROTIMI OLUTOYE
金额:
$21.58万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-01 至 2011-03-31
关键词:
AffectAmyloidAnimal ModelAreaBackBleomycinBloodBuffersCardiacCellsCicatrixCollagenComplexDataDermalDevelopmentEmotionalEnvironmentEnzyme-Linked Immunosorbent AssayFamily suidaeFemaleFibroblastsFibrosisFinancial costHarvestHealedHeartHistologicHypertrophic CicatrixIn VitroIndividualInjection of therapeutic agentIntraperitoneal InjectionsIntravenousIschemiaKeloidLeftLesionLungModalityModelingMolecular AnalysisMorbidity - disease rateMusMuscleMyofibroblastOrganPeripheral Blood Mononuclear CellPlasmaPreventionProcessProteinsPulmonary FibrosisRattusRecruitment ActivityReperfusion TherapyResearchRoleRouteSalineSerumSerum ProteinsSerum-Free Culture MediaSkinSocietiesTestingTherapeuticTissuesWestern BlottingWound Healingbasedesigndisabilityhealinghigh riskin vivointradermal injectionintraperitonealloss of functionmonocytemouse modelpreventpublic health relevanceresponsewound
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Scarring and fibrosis is accompanied by significant morbidity and loss of function. In dermal wounds and fibrotic lesions, a subset of circulating monocytes are recruited to the wound and differentiate into fibroblast-like cells called fibrocytes. A serum protein, serum amyloid P (SAP), can prevent this differentiation in vitro. In vivo, systemic administration of SAP reduced fibrosis in rat and mouse models of bleomycin-induced pulmonary fibrosis and in a murine ischemia-reperfusion model of cardiac fibrosis. We found that systemic administration or local injections of SAP caused delayed wound contraction and healing, and decreased myofibroblast content in murine dermal wounds. Using the female red Duroc pig (FRDP) model of hypertrophic scarring, we have preliminary data indicating that local injection of SAP into deep dermal wounds appears to reduce scarring and the collagen content of these wounds. Based on these observations, we propose to evaluate the role of SAP in wound fibrosis. The key hypothesis of this study is that SAP reduces the fibrotic response in an animal model of hypertrophic scar. To test this hypothesis, we propose the following specific aims: 1: Determine if FRDPs form excessive scars due to either abnormally low serum SAP levels or an abnormal response of fibrocyte precursors to SAP. FRDP serum SAP levels, the sera's ability to inhibit fibrocyte differentiation, and the rate of fibrocyte differentiation by FRDP monocytes will be compared with control Yorkshire pigs. 2. Characterize the effect of SAP on the dermal healing response of FRDP. The effect of intradermal injection of SAP on the healing of deep wounds on FRDP will be assessed by histological, immunohistochemical and molecular analysis of the wounds. 3: Determine the effects of different routes of administration of SAP on the wound healing response. The effect of systemic and local administration of SAP on wound healing will be compared. This highly focused study will evaluate the effect of this serum protein on the complex wound healing process. If our hypothesis proves to be correct, the impact would be substantial and significant, as we might be able to use SAP to prevent excessive scarring not only in hypertrophic scars and keloids but other fibrotic skin conditions and fibrosis in general. PUBLIC HEALTH RELEVANCE: Scar formation in the skin or internal organs can result in loss of function or severe disfigurement with a substantial emotional and financial cost to the individual and society at large. Modalities to treat or prevent scar formation would help reduce the disability resulting from these conditions. This project will evaluate the effect of a naturally occurring protein in the prevention of excessive scarring. Findings of this study would impact our treatment and/or prevention of scarring, be it of the skin, muscle or internal organs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NEAR INFRARED SPECTROSCOPY FOR HEMODYNAMIC MONITORING IN NEONATES UNDERGOING
-
批准号:8356758
-
项目类别:
-
资助金额:$0.01万
-
财政年份:2010
-
负责人:OLUYINKA OLUROTIMI OLUTOYE
-
依托单位:
SERUM AMYLOID P AND DERMAL WOUND FIBROSIS
-
批准号:7784433
-
项目类别:
-
资助金额:$13.56万
-
财政年份:2009
-
负责人:OLUYINKA OLUROTIMI OLUTOYE
-
依托单位:
ASSESSING GUT OXYGENATION IN PREMATURE INFANTS USING NEAR INFRARED SPECTROMET
-
批准号:8166678
-
项目类别:
-
资助金额:$0.81万
-
财政年份:2009
-
负责人:OLUYINKA OLUROTIMI OLUTOYE
-
依托单位:
ASSESSING GUT OXYGENATION IN PREMATURE INFANTS USING NEAR INFRARED SPECTROMET
-
批准号:7950624
-
项目类别:
-
资助金额:$4.25万
-
财政年份:2008
-
负责人:OLUYINKA OLUROTIMI OLUTOYE
-
依托单位:
Selectins and Fetal wound Healing
-
批准号:6847819
-
项目类别:
-
资助金额:$12.97万
-
财政年份:2004
-
负责人:OLUYINKA OLUROTIMI OLUTOYE
-
依托单位:
Selectins and Fetal wound Healing
-
批准号:7188526
-
项目类别:
-
资助金额:$12.97万
-
财政年份:2004
-
负责人:OLUYINKA OLUROTIMI OLUTOYE
-
依托单位:
Selectins and Fetal wound Healing
-
批准号:6719359
-
项目类别:
-
资助金额:$12.97万
-
财政年份:2004
-
负责人:OLUYINKA OLUROTIMI OLUTOYE
-
依托单位:
Selectins and Fetal wound Healing
-
批准号:7013210
-
项目类别:
-
资助金额:$12.97万
-
财政年份:2004
-
负责人:OLUYINKA OLUROTIMI OLUTOYE
-
依托单位:
PLATELETS AND FETAL WOUND HEALING
-
批准号:2171696
-
项目类别:
-
资助金额:$3.38万
-
财政年份:1995
-
负责人:OLUYINKA OLUROTIMI OLUTOYE
-
依托单位:
PLATELETS AND FETAL WOUND HEALING
-
批准号:2171695
-
项目类别:
-
资助金额:$3.25万
-
财政年份:1994
-
负责人:OLUYINKA OLUROTIMI OLUTOYE
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于聚金属氧酸盐对Amyloid蛋白的定点化学修饰及其在阿尔茨海默症治疗中的应用
-
批准号:22077118
-
项目类别:面上项目
-
资助金额:63.0万元
-
批准年份:2020
-
负责人:高楠
-
依托单位:
基于S1P通路探究Amyloid-β在干性年龄相关性黄斑变性中的作用
-
批准号:81870666
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2018
-
负责人:王海燕
-
依托单位:
Amyloid-beta-PirB 相互作用介导小胶质细胞表型和功能变化参与AD进展的机制研究
-
批准号:81601123
-
项目类别:青年科学基金项目
-
资助金额:17.0万元
-
批准年份:2016
-
负责人:都瑾
-
依托单位:
Beta-amyloid寡聚体特有的抗原表位多肽疫苗的研究
-
批准号:30971012
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2009
-
负责人:刘瑞田
-
依托单位:
抗阿兹海默病Beta-Amyloid寡聚物单链可变区抗体的筛选及其动物试验
-
批准号:30570622
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2005
-
负责人:刘瑞田
-
依托单位: